Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T13:31:11.137Z.
Calculation as of: 2026-10-06T13:31:11.137Z.
Quote observation: 2026-10-06T13:30:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ae4e4394aaeb0d5c8b7c6b49623c27b4c6984d6a5511a37bd4b8ffeab1df45fa
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Curanex Pharmaceuticals Inc Common Stock
Market Cap
$7.21M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$6.85M
EV/EBIT Ratio
N/A
TTM Avg
1748.82x
3Y Avg
1748.82x
5Y Avg
1748.82x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Curanex Pharmaceuticals Inc Common Stock (CURX) | $7.21M | N/A | N/A | N/A | N/A |
| KALA BIO, Inc. (KALA)vs › | $6.77M | N/A | N/A | N/A | N/A |
| Co-Diagnostics, Inc. (CODX)vs › | $7.00M | N/A | 1.45x | 7.74x | 7.74x |
| Aclarion, Inc. (ACON)vs › | $6.80M | N/A | N/A | N/A | N/A |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.85M | N/A | 1748.82x | 1748.82x | 1748.82x |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.58M | N/A | N/A | N/A | N/A |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.72M | N/A | N/A | N/A | N/A |
| Ensysce Biosciences, Inc. (ENSC)vs › | $6.41M | N/A | N/A | N/A | N/A |
| Longeveron Inc. (LGVN)vs › | $7.61M | N/A | N/A | N/A | N/A |
| Biomerica, Inc. (BMRA)vs › | $6.46M | N/A | 471.11x | 281.60x | 221.14x |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
